CJC-1295 / Ipamorelin
Synthetic peptide studied in animal and cell models for growth hormone output and selective hormone profile
Last updated: March 1, 2026
- Compound
- CJC-1295 / Ipamorelin
- Class
- Longevity peptide
- Summary
- Synthetic peptide studied in animal and cell models for growth hormone output, selective hormone profile, body composition support.
- Mechanism
- Multi-System Downstream Effects
- Research Status
- Phase II
- Routes Studied
- Subcutaneous injection
- Evidence Level
- Preclinical-promising · Clinically unproven
What Should You Know About CJC-1295 / Ipamorelin?
- What is CJC-1295 / Ipamorelin?
- CJC-1295 / Ipamorelin is a synthetic peptide studied in animal and cell models for growth hormone output and selective hormone profile.
- Is CJC-1295 / Ipamorelin clinically proven?
- No. Human evidence remains limited and does not establish CJC-1295 / Ipamorelin as clinically proven.
- What has CJC-1295 / Ipamorelin been studied for?
- CJC-1295 / Ipamorelin has been studied in preclinical models of growth hormone output, selective hormone profile, body composition support. These findings have not been confirmed in large-scale human trials.
- Is CJC-1295 / Ipamorelin approved?
- No. CJC-1295 / Ipamorelin is not an approved drug and remains a research compound.
What Is CJC-1295 / Ipamorelin?
CJC-1295 and Ipamorelin represent a synergistic combination of two distinct peptide compounds that work through complementary mechanisms to optimize natural growth hormone secretion. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH, modified with a Drug Affinity Complex (DAC) that extends its half-life from minutes to approximately 6-8 days. Ipamorelin is a selective growth hormone secretagogue (GHS), a pentapeptide that...
Evidence Summary
CJC-1295 / Ipamorelin is a research compound with promising biological signals but limited human validation. Most claims exceed current clinical evidence.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Growth Hormone Output | Limited |
| Selective Hormone Profile | Limited |
| Body Composition Support | Limited |
| Recovery & Longevity Support | Limited |
| Human clinical evidence | Limited |
| Safety data | Insufficient |
Editorial Position
CJC-1295 / Ipamorelin is best understood as a compound with emerging clinical evidence that has not yet reached definitive conclusions. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Not approved as a therapeutic drug by major regulators
- Safety profile not established in large human populations
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for CJC-1295 / Ipamorelin is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has CJC-1295 / Ipamorelin Been Studied For?
Research areas where CJC-1295 / Ipamorelin has been investigated in published studies
-
Growth Hormone Output CJC-1295 / Ipamorelin has been studied in animal models of growth hormone output. These findings have not been confirmed in controlled human trials.
-
Selective Hormone Profile CJC-1295 / Ipamorelin has been studied in animal models of selective hormone profile. These findings have not been confirmed in controlled human trials.
-
Body Composition Support CJC-1295 / Ipamorelin has been studied in animal models of body composition support. These findings have not been confirmed in controlled human trials.
-
Recovery & Longevity Support CJC-1295 / Ipamorelin has been studied in animal models of recovery & longevity support. These findings have not been confirmed in controlled human trials.
How Does CJC-1295 / Ipamorelin Work?
These mechanisms have been observed in preclinical models. They are plausible but have not been linked to proven clinical outcomes in humans.
- 01 Ipamorelin Activates GHS-R1a Receptor
- 02 CJC-1295 Amplifies GHRH Signaling
- 03 Synergistic GH Pulse Release
- 04 Hepatic IGF-1 Production
Not sure if CJC-1295 / Ipamorelin is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about CJC-1295 / Ipamorelin.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate CJC-1295 / Ipamorelin
How Is CJC-1295 / Ipamorelin Administered?
CJC-1295 / Ipamorelin is available via Subcutaneous injection, auto-injector pen. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of CJC-1295 / Ipamorelin?
What Conditions Has CJC-1295 / Ipamorelin Been Linked To?
Have Questions About CJC-1295 / Ipamorelin?
Published studies on CJC-1295 / Ipamorelin can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
CJC-1295 / Ipamorelin is available as a research compound in Thailand. Consult a qualified specialist to discuss whether it is appropriate for your needs.
A qualified specialist experienced with peptide therapies can help you understand the current evidence and determine suitability.
Ready to discuss CJC-1295 / Ipamorelin with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026